Skip to content
Kronos Bio logo — We’re focused on creating a world where no life is cut short...

Kronos Bio

We’re focused on creating a world where no life is cut short by cancer or other serious diseases.

Founded 2017 United States San Mateo, United States 70 employees Private Equity Total: $278.00M Biotechnology, Health and Wellness

General Information

Company Name Kronos Bio
Founded Year 2017
Location United States San Mateo, United States
Founders / Decision Makers
Team member Team member
Employees 70
Industries Biotechnology, Health and Wellness
Funding Stage Private Equity
Social

BounceWatch is an independent company data service, not affiliated with Kronos Bio. To contact Kronos Bio, visit kronosbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Kronos Bio compare?

A PDF of Kronos Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Kronos Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Kronos Bio

Kronos Bio is a clinical-stage biopharmaceutical company with a mission to combat cancer and serious diseases by targeting dysregulated transcription. The company's current pipeline includes KB-0742, a CDK9 inhibitor under evaluation for MYC-dependent tumors and KB-9558, targeting the KAT domain of p300 for multiple myeloma treatment. In addition, Kronos Bio has partnered with Genentech to develop novel oncology therapies. Founded in 2017 and headquartered in the United States, Kronos Bio's last investment round of $155.00M was led by a consortium of notable investors including GV, BlackRock, Invus, T. Rowe Price, Commodore Capital, Fidelity, Nextech Invest, Vida Ventures, Woodline Partners, and Surveyor Capital in August 25, 2020. With a promising approach to tackling cancer at the transcriptional level, Kronos Bio presents an intriguing opportunity for investors seeking impactful ventures in the biotechnology space. For more details, visit: [Kronos Bio Community Guidelines](https:\/\/bit.ly\/3FfcDQW).

Business keywords: biopharmaceutical company, clinical-stage, therapeutics, CDK9 inhibitor, transcription factor, oncology, cancer treatment, myc-dependent tumors, transcriptional addiction, discovery collaboration, Genentech partnership, p300 KAT domain, multiple myeloma, transcriptional targets, precision medicine

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Private Equity Round $155.00M 10
GV, BlackRock +8
25 Aug 2020
Series A $105.00M -
18 Jul 2019
Seed Round $18.00M -
05 Jun 2018

Kronos Bio Alternatives & Competitors

View All Alternatives
Kronos Bio vs

Targeted Therapy Delivered

Acquired
39 employees
Biotechnology, Health and Wellness
Kronos Bio vs

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developin...

Post-IPO Equity
10 employees
Biotechnology, Health Care
Kronos Bio vs
Simcha Therapeutics
Simcha Therapeutics United States

Overcoming biological challenges in clinically translatable pathways.

Series B
15 employees
Biotechnology, Health and Wellness

FAQ About Kronos Bio

We’re focused on creating a world where no life is cut short by cancer or other serious diseases.
Kronos Bio was founded in 2017.
Kronos Bio is headquartered in San Mateo, United States.
Kronos Bio operates in Biotechnology and Health and Wellness. Its work centres on biopharmaceutical company, clinical-stage, therapeutics and CDK9 inhibitor.
Kronos Bio has approximately 70 employees.
Kronos Bio has completed 3 funding rounds, raising a total of $278.00M. The latest funding stage is Private Equity.
Top alternatives and competitors to Kronos Bio include Lisata Therapeutics, Inc., Cascadian Therapeutics, Inc., Simcha Therapeutics, SOLID Therapeutics, Treadwell Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Kronos Bio and Lisata Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Kronos Bio, https://www.bouncewatch.com/company/kronos-bio, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout